Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mader

Showing results (211-220 of 221) with videos related to

Pageof 23
Sort By:
Cellular and Molecular Life Sciences : CMLS|December 26, 2016
Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca<sup>2+</sup> signallingSerena Stadler, Chi Huu Nguyen, Helga Schachner, et al.
Journal of Medicinal Chemistry|February 16, 2021
A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6Yudao Shen, Fengling Li, Magdalena M Szewczyk, et al.
Nature Cancer|July 11, 2022
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1Nathaniel W Mabe, Min Huang, Guillermo N Dalton, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
Cancer Letters|December 3, 2014
Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasationIzabella Kiss, Christine Unger, Chi Nguyen Huu, et al.
Nature Communications|July 11, 2024
A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis BullosaGernot Neumayer, Jessica L Torkelson, Shengdi Li, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|July 30, 2015
The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-κB-driven tumour intravasationChristine Unger, Izabella Kiss, Andrea Vasas, et al.
Journal of Medicinal Chemistry|October 16, 2004
Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agentsKaren L Lobb, Philip A Hipskind, James A Aikins, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Nature Chemical Biology|July 22, 2015
The promise and peril of chemical probesCheryl H Arrowsmith, James E Audia, Christopher Austin, et al.
Pageof 23

Showing results (211-220 of 221) with videos related to

Sort By:
Pageof 23
Cellular and Molecular Life Sciences : CMLS|December 26, 2016
Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca<sup>2+</sup> signallingSerena Stadler, Chi Huu Nguyen, Helga Schachner, et al.
Journal of Medicinal Chemistry|February 16, 2021
A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6Yudao Shen, Fengling Li, Magdalena M Szewczyk, et al.
Nature Cancer|July 11, 2022
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1Nathaniel W Mabe, Min Huang, Guillermo N Dalton, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
Cancer Letters|December 3, 2014
Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasationIzabella Kiss, Christine Unger, Chi Nguyen Huu, et al.
Nature Communications|July 11, 2024
A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis BullosaGernot Neumayer, Jessica L Torkelson, Shengdi Li, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|July 30, 2015
The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-κB-driven tumour intravasationChristine Unger, Izabella Kiss, Andrea Vasas, et al.
Journal of Medicinal Chemistry|October 16, 2004
Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agentsKaren L Lobb, Philip A Hipskind, James A Aikins, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Nature Chemical Biology|July 22, 2015
The promise and peril of chemical probesCheryl H Arrowsmith, James E Audia, Christopher Austin, et al.
Pageof 23